Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01984424
First received: November 8, 2013
Last updated: September 27, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: November 2017
  Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 13, 2016
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):